学术周报 · IF≥10 或专科旗舰刊
肾内科领域文献阅读汇编
2026年第46周 (2026-11-13) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Kidney international | 3 | IF 21.8 |
| Journal of the American Society of Nephrology : JASN | 2 | IF 9.7 |
| American journal of kidney diseases : the official journal of the National Kidney Foundation | 2 | IF 9.4 |
| European heart journal | 2 | IF 45.3 |
| Circulation research | 2 | IF 18.0 |
| Food chemistry | 2 | IF 10.4 |
| Pharmacological research | 1 | IF 12.2 |
| Annual review of animal biosciences | 1 | IF 12.3 |
| JAMA cardiology | 1 | IF 15.2 |
| Nature metabolism | 1 | IF 27.5 |
1慢性肾脏病 CKD (13篇)
临床研究 (9篇)
Doctors increasingly rely on models that predict a patient's risk of future health problems. These models only work well when the patients they were built on resemble the patients being treated now, in illness type, care setting, and stage of disease. This is easy to see when the mismatch is obvious: a model built on hospital patients may not suit those seen in a family doctor's office. The same problem is harder to appreciate when it comes from where a patient sits on a chronic illness journey. Using severe chronic kidney disease as an example, this review shows that a model built from patients who have recently progressed to this more severe stage works better for patients at that same point, while a model built from patients who have lived with the disease for years works better for those further along. This review offers practical steps to keep predictions aligned with the patients they serve.
中文摘要:医生越来越多地依赖预测患者未来健康风险的模型。这些模型仅在所基于的患者与当前接受治疗的患者在疾病类型、护理环境和疾病阶段上相似时才能有效工作。当不匹配显而易见时这一点很容易看出例如基于住院患者建立的模型可能不适合家庭医生诊所中的患者。当问题源于患者在慢性病旅程中的位置时同样的问题更难被察觉。以严重慢性肾脏病为例本综述表明基于近期进展到该更严重阶段的患者建立的模型更适合处于同一阶段的患者而基于患病多年的患者建立的模型则更适合病程更晚期的患者。本综述提供了保持预测与服务对象一致的实用步骤。
Apolipoprotein L1 (APOL1) variants are common in individuals of African descent and increase risk of chronic kidney disease (CKD). Renin-angiotensin system inhibitors (RASis) are a mainstay of therapy for hypertension and proteinuric CKD but were not historically recommended as first-line anti-hypertensive therapy in Black individuals. Here, we evaluated RASis versus other antihypertensive therapy on kidney outcomes in Black individuals by APOL1 genotype. We included Black participants with APOL1 genotyping on first-line anti-hypertensive therapy from the Chronic Renal Insufficiency Cohort (CRIC) and Systolic Blood Pressure Intervention Trial (SPRINT). We evaluated whether the impact of RASi-prescription on kidney outcomes was modified by APOL1 risk allele number or baseline albuminuria, using Cox models with inverse probability of treatment weighting and marginal structural models. A total of 3418 participants (62% from SPRINT), 40%, 44% and 16% carrying zero, one and two APOL1 risk alleles, respectively, were included. RASi-use compared to other first-line antihypertensive therapy was associated with a comparably lower risk of the kidney outcome in individuals with zero (hazard ratio (HR) 0.62 [95% confidence interval (CI) 0.44-0.87]), one (HR 0.68 [95% CI 0.49-0.94]) or two risk alleles (HR 0.59 [95% CI 0.40-0.86]). This benefit was driven by albuminuric participants, but estimates were similarly low for RASi-use compared to other antihypertensive therapy in albuminuric (HR 0.62, 95% CI [0.41-0.93]) and non-albuminuric (HR 0.37, 95% CI [0.13-1.08]) participants with two APOL1 risk alleles, although the estimate was imprecise in non-albuminuric participants. RASi-based therapy, addressed as a time-updated pooled treatment, provided similar benefit across APOL1 genotypes, driven by albuminuric participants. Among individuals with two APOL1 risk alleles, outcomes were similar regardless of baseline albuminuria. However, further studies are needed due to small sample sizes and the inability of statistical methods to capture clinical variables that may have affected prescription changes.
中文摘要:载脂蛋白L1(APOL1)变异在非洲裔个体中常见且增加慢性肾脏病(CKD)风险。肾素-血管紧张素系统抑制剂(RASis)是高血压和蛋白尿性CKD的主要治疗手段,但历史上未推荐作为黑人的首选降压治疗。本研究评估了不同APOL1基因型黑人个体的肾脏结局受RASis与其他降压药的影响差异。研究纳入来自慢性肾脏病队列(CRIC)和收缩压干预试验(SPRINT)中接受一线降压治疗且完成APOL1基因分型的黑人参与者。利用逆概率治疗加权Cox模型和边际结构模型,评估RASi处方对肾脏结局的影响是否受APOL1风险等位基因数量或基线白蛋白尿修饰。共纳入3418名参与者(62%来自SPRINT),其中携带零、一和两个APOL1风险等位基因的比例分别为40%、44%和16%。与使用其他一线降压药相比,使用RASis在携带零个(HR 0.62 [95% CI 0.44-0.87])、一个(HR 0.68 [95% CI 0.49-0.94])或两个风险等位基因(HR 0.59 [95% CI 0.40-0.86])的个体中均与较低的肾脏结局风险相关。这种益处主要由白蛋白尿参与者驱动,但在携带两个APOL1风险等位基因的白蛋白尿(HR 0.62, 95% CI [0.41-0.93])和非白蛋白尿(HR 0.37, 95% CI [0.13-1.08])参与者中,与使用其他降压药相比估计值同样较低,尽管非白蛋白尿参与者的估计值不够精确。作为时间更新的合并治疗,基于RASis的治疗在不同APOL1基因型中提供了相似的益处,主要由白蛋白尿参与者驱动。在携带两个APOL1风险等位基因的个体中,无论基线白蛋白尿如何,结局相似。然而,由于样本量较小且统计方法无法捕捉可能影响处方变化的临床变量,仍需进一步研究。
Chronic kidney disease (CKD) remains underdiagnosed and undertreated despite substantial cardiovascular and mortality risks. Guidelines recommend annual testing with estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) in at-risk populations, and a growing number of guideline-directed medical therapies (GDMT) improve kidney and cardiovascular outcomes in CKD. We conducted a scoping review of controlled implementation studies to identify effective strategies for improving CKD testing and GDMT delivery and define priorities for future implementation trials. Following a registered protocol and PRISMA extension for Scoping Reviews (PRISMA-ScR) guidance, we searched MEDLINE, Embase, and the Web of Science Core Collection from database inception through June 9, 2026 for English-language prospective controlled studies. Eligible studies compared an implementation strategy with usual care or another control condition. We charted study characteristics and outcomes using standardized templates and synthesized findings by objective, strategy, setting, design, and target population. We included 26 reports from 24 studies (N=7 testing, N=17 treatment). Six of 7 studies increased CKD testing, with the largest gains from patient-directed home testing and automated laboratory ordering paired with clinical decision support. However, increased testing seldom translated into increased CKD diagnosis or GDMT prescriptions. Of implementation efforts focused on CKD treatment, only 5 of 17 studies increased GDMT prescribing. Passive, single-touch strategies, including isolated alerts, one-time prompts, and registries without active outreach, rarely changed prescribing. In contrast, longitudinal strategies that incorporated pharmacist- or advanced practice provider-led management, nephrologist-supported multidisciplinary care, or proactive registry-based outreach more consistently increased GDMT exposure and sometimes improved intermediate clinical outcomes. Among 24 prospective controlled studies, patient-directed home testing and automated laboratory ordering paired with clinical decision support increased CKD testing, but increased testing seldom led to CKD diagnosis or GDMT prescribing. Only 5 of 17 treatment studies increased GDMT prescribing, all through longitudinal, team-based care.
中文摘要:尽管慢性肾脏病(CKD)存在显著的心血管和死亡风险,但其诊断和治疗仍然不足。指南推荐对高危人群每年进行估算肾小球滤过率(eGFR)和尿白蛋白肌酐比值(UACR)检测,且越来越多的指南指导医疗疗法(GDMT)可改善 CKD 患者的肾脏和心血管结局。我们开展了一项针对对照实施研究的范围综述,旨在确定提高 CKD 检测和 GDMT 交付的有效策略,并为未来的实施试验定义优先事项。遵循注册方案和 PRISMA-ScR 扩展指南,我们检索了从数据库建库至 2026 年 6 月 9 日的 MEDLINE、Embase 和 Web of Science 核心合集中的英文前瞻性对照研究。符合条件的研究比较了实施策略与常规护理或其他对照条件。我们使用标准化模板绘制了研究特征和结果,并按目标、策略、设置、设计和目标人群综合了发现结果。我们纳入了来自 24 项研究的 26 份报告(其中 N=7 为检测研究,N=17 为治疗研究)。7 项检测研究中有 6 项提高了 CKD 检测率,其中患者主导的家庭检测与自动化实验室订单结合临床决策支持带来的增长最大。然而,检测率的增加很少转化为 CKD 诊断或 GDMT 处方的增加。在针对 CKD 治疗的实施努力中,17 项研究中仅有 5 项增加了 GDMT 处方。被动、单次接触的策略(包括孤立警报、一次性提示以及缺乏主动外展的登记系统)很少改变处方行为。相比之下,纵向策略(包括由药剂师或高级实践提供者主导的管理、肾病学家支持的多学科护理,或基于登记系统的主动外展)更一致地增加了 GDMT 暴露量,并有时改善了中间临床结局。在 24 项前瞻性对照研究中,患者主导的家庭检测和与临床决策支持结合的自动化实验室订单提高了 CKD 检测率,但检测率的增加很少导致 CKD 诊断或 GDMT 处方的增加。17 项治疗研究中仅有 5 项增加了 GDMT 处方,且均通过纵向团队护理实现。
Occult cerebrovascular diseases (OCCD) including extracranial and intracranial atherosclerotic disease (ECAD and ICAD) and cerebral small vessel disease (CSVD) are asymptomatic cerebrovascular abnormalities associated with future risk of stroke and dementia. Although chronic kidney disease (CKD) is strongly associated with adverse brain health outcomes, the breadth of evidence regarding OCCD in people with CKD has not been comprehensively characterized. This scoping review summarizes the available literature on OCCD among adults with CKD without clinically overt cerebrovascular disease. PubMed, EMBASE, Web of Science, and Scopus were searched for studies published between January 2000 and July 2025. Peer-reviewed studies reporting the frequency or characteristics of OCCD manifestations in adults with CKD without a known history of stroke or transient ischemic attack. Two reviewers independently screened studies and extracted data on study characteristics, CKD definitions, neuroimaging modalities, and reported OCCD findings. Methodological quality was assessed using a modified Newcastle-Ottawa Scale. Forty-six studies comprising 5,153 participants with CKD were included. Study populations varied substantially with respect to CKD stage, dialysis status, study design, and imaging methodology. Two studies evaluating ICAD reported moderate-to-severe intracranial stenosis in approximately one-quarter of participants with CKD. Across studies evaluating ECAD, the frequency of significant extracranial carotid stenosis ranged from approximately 3% in patients with non-dialysis-dependent CKD to 28% among patients receiving dialysis. Thirty-eight studies evaluated manifestations of CSVD, including cerebral microbleeds, silent cerebral infarctions, white matter hyperintensities, and enlarged perivascular spaces. Several studies suggested a greater burden of CSVD manifestations among patients with advanced CKD or dialysis dependence. Reported frequencies varied considerably across studies. Considerable heterogeneity in study populations, CKD definitions, imaging protocols, and outcome ascertainment methods limited direct comparison across studies. Occult cerebrovascular abnormalities are frequently reported across diverse CKD populations, particularly among patients with advanced kidney disease. Variation in the prevalence of abnormalities may reflect differences in CKD severity, participant characteristics, neuroimaging protocols, and outcome definitions. These findings highlight the need for standardized neuroimaging approaches and prospective studies to better characterize the clinical implications of OCCD in CKD.
中文摘要:隐匿性脑血管疾病包括颅外和颅内动脉粥样硬化性疾病以及脑小血管病,是与未来卒中和痴呆风险相关的无症状脑血管异常。尽管慢性肾脏病与不良脑健康结局密切相关,但关于慢性肾脏病患者中隐匿性脑血管疾病的证据广度尚未得到全面描述。本范围综述总结了成人慢性肾脏病且无临床明显脑血管疾病患者的相关文献。检索了2000年1月至2025年7月发表的PubMed、EMBASE、Web of Science和Scopus数据库中的同行评审研究,这些研究报告了无卒中或短暂性脑缺血发作病史的成人慢性肾脏病患者中隐匿性脑血管疾病表现的发生率或特征。两名审稿人独立筛选研究并提取研究特征、慢性肾脏病定义、神经影像模态及报告的隐匿性脑血管疾病发现的数据。使用改良纽卡斯尔-渥太华量表评估方法学质量。纳入46项研究,共5153名慢性肾脏病患者。研究人群在慢性肾脏病分期、透析状态、研究设计和成像方法方面差异显著。两项评估颅内动脉粥样硬化性疾病的研究报告约四分之一的慢性肾脏病患者存在中度至重度颅内狭窄。在评估颅外动脉粥样硬化性疾病的研究中,显著颅外颈动脉狭窄的发生率在非依赖透析的慢性肾脏病患者中约为3%,在接受透析的患者中为28%。38项研究评估了脑小血管病表现,包括脑微出血、静息性脑梗死、白质高信号和扩大血管周围间隙。多项研究表明,晚期慢性肾脏病或依赖透析的患者中脑小血管病表现负担更重。报告的发生率在不同研究中差异很大。研究人群、慢性肾脏病定义、成像方案和结局确定方法的显著异质性限制了研究的直接比较。隐匿性脑血管异常在多种慢性肾脏病人群中频繁报道,特别是在晚期肾病患者中。异常患病率的差异可能反映了慢性肾脏病严重程度、参与者特征、神经影像方案和结局定义的差异。这些发现强调了标准化神经影像方法和前瞻性研究以更好地描述慢性肾脏病中隐匿性脑血管疾病的临床意义的必要性。
In the Semaglutide Cardiovascular Outcomes Trial (SOUL), oral semaglutide reduced the risk of a first 3-point major adverse cardiovascular event (3-P MACE; including nonfatal myocardial infarction, nonfatal stroke, and cardiovascular [CV] death). Total event analyses, assessing both first and subsequent events, can contribute to a better understanding of the impact of interventions on the total burden of disease; however, the effects of oral semaglutide on subsequent events are unknown. To evaluate the effect of oral semaglutide vs placebo on total 3-P MACE. This was a prespecified secondary analysis of the double-blind, placebo-controlled, event-driven, phase 3b SOUL randomized clinical trial, conducted from June 2019 to September 2024 with a median (IQR) follow-up of 49.5 (44.0-54.9) months at 444 centers in 33 countries. Participants had type 2 diabetes and atherosclerotic CV disease and/or chronic kidney disease. Data were analyzed from December 2024 to August 2025. Once-daily oral semaglutide (maximal dose 14 mg) or placebo, in addition standard of care. Occurrence of total (first and subsequent) 3-P MACE. Overall, 9650 participants (median [IQR] age, 66.0 [61.0-72.0] years; 6860 [71.1%] male) were randomized 1:1. In the oral semaglutide group, fewer first and subsequent 3-P MACE occurred (683 total; 579 first and 104 subsequent events) compared with placebo (791 total; 668 first and 123 subsequent events) (mean ratio, 0.86; 95% CI, 0.76-0.97; P = .01). For the end point of 3-P MACE plus non-CV death, there were 138 fewer total events with oral semaglutide (910 events) compared with placebo (1048 events) (mean ratio, 0.87; 95% CI, 0.79-0.95; P = .004). As previously reported, adverse events led to treatment discontinuation in 749 (15.5%) and 559 (11.6%) participants receiving oral semaglutide and placebo, respectively. Oral semaglutide reduced the risk of first plus subsequent 3-P MACE vs placebo, highlighting the benefit of oral semaglutide in reducing the total burden of clinical morbidity and mortality in this high-risk population. ClinicalTrials.gov Identifier: NCT03914326.
中文摘要:在Semaglutide心血管结局试验(SOUL)中,口服司美格鲁肽降低了首次3点主要不良心血管事件(3-P MACE;包括非致死性心肌梗死、非致死性卒中和心血管死亡)的风险。评估首次和后续事件的总事件分析有助于更好地理解干预措施对疾病总负担的影响;然而,口服司美格鲁肽对后续事件的影响尚不清楚。本研究旨在评估口服司美格鲁肽与安慰剂对总3-P MACE的影响。这是一项预先指定的二次分析,基于2019年6月至2024年9月进行的为期33个国家444个中心的随机对照试验SOUL,中位(四分位距)随访时间为49.5(44.0-54.9)个月。参与者患有2型糖尿病和动脉粥样硬化性心血管疾病和/或慢性肾脏病。数据分析时间为2024年12月至2025年8月。每日一次口服司美格鲁肽(最大剂量14 mg)或安慰剂,加上标准护理。主要结局为总(首次和后续)3-P MACE的发生情况。总体而言,9650名参与者(中位年龄66.0岁;男性6860名占71.1%)以1:1比例随机分组。在口服司美格鲁肽组中,首次和后续3-P MACE发生较少(共683例;579例首次和104例后续事件),而安慰剂组为791例(668例首次和123例后续事件)(均值比0.86;95% CI 0.76-0.97;P = .01)。对于3-P MACE加非心血管死亡的终点,口服司美格鲁肽组总事件减少了138例(910例),而安慰剂组为1048例(均值比0.87;95% CI 0.79-0.95;P = .004)。如前所述,不良事件导致接受口服司美格鲁肽和安慰剂的参与者分别有749名(15.5%)和559名(11.6%)停药。与安慰剂相比,口服司美格鲁肽降低了首次加后续3-P MACE的风险,突出了口服司美格鲁肽在降低这一高风险人群临床发病率和死亡率总负担方面的益处。ClinicalTrials.gov标识符:NCT03914326。
While the prevalence, drivers, and impact of cardiometabolic risk factors are known to differ between women and men, less is known about sex differences in the cardiovascular-kidney-metabolic (CKM) syndrome. In this prespecified analysis, individual participant-level data were pooled from two trials of chronic kidney disease and type 2 diabetes (FIDELIO-DKD and FIGARO-DKD) and a trial of heart failure (HF) with mildly reduced or preserved ejection fraction (FINEARTS-HF). The risk of first HF hospitalization, cardiovascular death, major adverse cardiovascular events, kidney composite outcome, and all-cause death, was compared between men and women using adjusted Cox regression models. Treatment effect heterogeneity in response to finerenone was evaluated using interaction analyses. Of the 18 991 participants in FINE-HEART, 6664 (35%) were women. Compared with men, women were slightly older (69 vs 67 years) and had a lower median urine albumin-to-creatinine ratio (183 vs 337 mg/g). Women were more likely to have Stage 4 CKM syndrome but less likely to receive medical therapies commonly indicated for the management of CKM conditions at baseline, such as aspirin, statins, renin-angiotensin system inhibitors, sodium-glucose co-transporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists. During a median follow-up of 2.9 years, both women and men had similarly high rates of HF hospitalization or cardiovascular death (4.8 vs 3.9 per 100 patient-years, adjusted hazard ratio [HR] 0.97, 95% confidence interval [CI] 0.89-1.06, P = .52) but lower risk of all-cause mortality (adjusted HR 0.83, 95% CI 0.76-0.91, P < .001) compared with men. There was no evidence of treatment heterogeneity by sex with finerenone in reducing cardiovascular, kidney, and mortality outcomes (all Pinteraction >.05). In this pooled analysis of individuals with advanced CKM syndrome, women had a higher burden of multimorbidity and were less likely to receive commonly indicated CKM therapies than men. Finerenone conferred consistent benefits in women and men, reinforcing its use while underscoring persistent sex-based treatment disparities in CKM care. PROSPERO identifier: CRD42024570467.
中文摘要:尽管已知心血管代谢危险因素在女性和男性中的患病率、驱动因素及影响存在差异,但关于心血管-肾脏-代谢(CKM)综合征的性别差异知之甚少。在这项预设分析中,我们汇总了来自两项慢性肾脏病和2型糖尿病试验(FIDELIO-DKD和FIGARO-DKD)以及一项射血分数轻度降低或保留的心力衰竭(HF)试验(FINEARTS-HF)的个体参与者水平数据。使用调整后的Cox回归模型比较了男性和女性首次心力衰竭住院、心血管死亡、主要不良心血管事件、肾脏复合结局及全因死亡的风险。通过交互作用分析评估了非奈利酮治疗反应的异质性。在FINE-HEART的18991名参与者中,6664名(35%)为女性。与男性相比,女性年龄稍大(69岁对67岁),尿白蛋白肌酐比中位数较低(183对337 mg/g)。女性更可能处于CKM综合征第4期,但在基线时接受常用于管理CKM状况的药物治疗(如阿司匹林、他汀类药物、肾素-血管紧张素系统抑制剂、钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂)的可能性较低。在中位随访2.9年期间,女性和男性的心力衰竭住院或心血管死亡率均较高(4.8对3.9每100患者年,调整后的风险比[HR] 0.97,95%置信区间[CI] 0.89-1.06,P = .52),但全因死亡风险低于男性(调整后的HR 0.83,95% CI 0.76-0.91,P < .001)。没有证据表明非奈利酮在降低心血管、肾脏和死亡结局方面存在性别治疗异质性(所有交互作用P值均>.05)。在这项针对晚期CKM综合征个体的汇总分析中,女性合并症负担更重,接受常用CKM治疗的可能性低于男性。非奈利酮为女性和男性带来了一致的益处,强化了其临床应用,同时突显了CKM护理中持续存在的基于性别的治疗差异。PROSPERO注册号:CRD42024570467。
Low-value care costs more than $100 billion annually and remains pervasive despite decades of evidence documenting its clinical and financial harms. While several US states have begun discouraging its use, the feasibility of such statewide interventions in partnership with large health systems remains unknown. To investigate the effectiveness of a clinician-led, multistakeholder, statewide initiative to reduce low-value care in the Commonwealth of Virginia. This quality improvement study used a difference-in-differences analyses comparing low-value service changes among patients attributed to 6 health systems vs 12 control systems in the Commonwealth of Virginia preintervention (January 1 to December 31, 2019) vs postintervention (January 1 to December 31, 2022). Any patient eligible to receive 1 or more of the 9 measured low-value services in the 18 health systems evaluated were included. Data were analyzed between December 1, 2023, and September 1, 2026. The intervention, Smarter Care Virginia, included health system financial support, clinician education, and quarterly peer-comparison performance scorecards. The primary outcome was the percentage of patients receiving any of 9 selected low-value services: (1-3) preoperative laboratory, imaging, and cardiac testing; (4-5) electrocardiogram/cardiac screening and cardiac stress testing; (6-7) diagnostic imaging and opioids for acute back pain; (8) advanced diagnostic eye imaging; and (9) peripherally inserted central catheter lines for patients with chronic kidney disease. Secondary outcomes included adverse events (eg, myocardial infarction-related hospitalization) and per-capita spending on the 9 low-value services. A total of 17 223 clinicians (7222 in the intervention group and 10 001 in the control group) and 4.5 million patients (approximately 68% of Virginia's adult population) were identified. In 2019, 10.5% of patients in the intervention group and 10.7% of patients in the control group received 1 or more low-value services; in 2021 to 2022, rates declined to 8.5% and 9.1%, respectively. The intervention was associated with 10.4% fewer patients receiving 1 or more low-value services (absolute reduction, -1.1 percentage points; 95% CI, -2.1 to -0.1 percentage points; P = .04). There was no statistically significant change in adverse events (0.03%; 95% CI, -0.02% to 0.03%; P = .84) or spending on the 9 low-value services ($0.33; 95% CI, -$3.43 to $4.11). In this quality improvement study, a statewide, clinician-led initiative was associated with a small but statistically significant reduction in low-value care delivery without evidence of harm. Achieving larger reductions may require combining such health system-driven efforts with additional strategies, such as payment reform and physician and hospital accountability, that discourage the use of low-value care.
中文摘要:低价值医疗每年花费超过1000亿美元,尽管已有数十年证据记录其临床和经济危害,但其仍普遍存在。虽然美国多个州已开始劝阻使用低价值医疗,但此类全州性干预措施与大型卫生系统合作的可行性尚不清楚。本研究旨在调查弗吉尼亚州一项由临床医生主导的多利益相关方全州性倡议在减少低价值医疗方面的有效性。这项质量改进研究采用双重差分分析,比较了干预前(2019年1月1日至12月31日)与干预后(2022年1月1日至12月31日)弗吉尼亚州6个卫生系统 vs 12个对照系统中患者的低价值服务变化。评估的18个卫生系统中,任何有资格接受9项测量低价值服务中一项或多项的患者均被纳入。数据于2023年12月1日至2026年9月1日期间进行分析。干预措施Smarter Care Virginia包括卫生系统财务支持、临床医生教育和季度同行比较绩效评分卡。主要结局是接受9项选定低价值服务中任何一项的患者百分比:(1-3)术前实验室检查、影像学和心脏测试;(4-5)心电图/心脏筛查和心脏压力测试;(6-7)急性背痛患者的诊断影像学和阿片类药物;(8)高级诊断性眼部影像学;以及(9)慢性肾脏病患者的经外周静脉置入中心静脉导管。次要结局包括不良事件(例如心肌梗死相关住院)和9项低价值服务的人均支出。共确定17223名临床医生(干预组7222名,对照组10001名)和450万名患者(约占弗吉尼亚州成年人口的68%)。2019年,干预组和对照组分别有10.5%和10.7%的患者接受了一项或多项低价值服务;在2021年至2022年期间,比例下降至8.5%和9.1%。该干预措施与接受一项或多项低价值服务的患者减少10.4%相关(绝对减少-1.1个百分点;95% CI,-2.1至-0.1个百分点;P = .04)。不良事件(0.03%;95% CI,-0.02%至0.03%;P = .84)或9项低价值服务的支出($0.33;95% CI,-$3.43至$4.11)均无统计学显著变化。在这项质量改进研究中,全州性的临床医生主导倡议与低价值医疗交付的小幅但统计学显著的减少相关,且无伤害证据。实现更大的减少可能需要将此类卫生系统驱动的努力与其他策略相结合,例如支付改革和医生及医院的问责制,以劝阻使用低价值医疗。
B-cell dysregulation contributes to IgA nephropathy (IgAN). Rituximab (RTX) targets CD20-positive B cells, but its efficacy in adults with IgAN receiving stable renin-angiotensin system inhibitor (RASI) therapy remains uncertain. This study sought to evaluate the efficacy and safety of RTX combined with RASI therapy compared with RASI therapy alone. Multicenter, randomized, controlled trial. Chinese adults with biopsy-proven IgAN across 10 centers, with 24-hour urine total protein (UTP) >1 g/day despite ≥3 months RASI therapy, and blood pressure <130/80 mmHg. RTX plus RASI versus RASI alone for 12 months OUTCOMES: Primary: 24-hour UTP change at month 12. Secondary continuous: changes in 24-hour UTP at month 6 and in eGFR and serum Gd-IgA1 at month 12. Secondary categorical: ≥50% reduction in 24-hour UTP at months 6 and 12, ≥50% eGFR decline or doubling of serum creatinine, and ESKD. adverse events, serious adverse events, and infections. Exploratory analyses examined outcomes through month 24. Among the 106 participants randomized (53 per group), 24-hour UTP change at 12 months was similar between groups (adjusted GMR, 1.05; 95% CI, 0.80-1.36). Median change of 24-hour UTP was -0.21 g/day for RTX and -0.26 g/day for RASI. No statistically significant differences were observed in eGFR (adjusted mean difference, 3.80 mL/min/1.73 m2; 95% CI, -0.47 to 8.06), Gd-IgA1 (adjusted GMR, 1.04; 95% CI, 0.87-1.24), or the proportion achieving a ≥50% reduction in 24-hour UTP (15.1% vs 20.8%). Adverse events occurred at similar rates between two groups; no events of ≥50% eGFR decline, doubling of serum creatinine, or ESKD occurred during the 12-month treatment period. These findings were consistent with analyses that included outcome data through month 24. The follow-up period was relatively short, and only Asian patients were enrolled. No additional reduction in proteinuria or preservation of kidney function was observed with the addition of RTX to optimized RASI-based therapy in patients with IgAN. Grants from government (National Key Research and Development Program, Major International [Regional] Joint Research Program of China, National Natural Science Foundation of China, National Facility for Translational Medicine [Shanghai], Shanghai 'Rising Stars of Medical Talent' Youth Development Program), academic (Shanghai Shenkang Hospital Development Center), and non-profit (International Society of Nephrology) sources.
中文摘要:B细胞失调参与IgA肾病(IgAN)的发病。利妥昔单抗(RTX)靶向CD20阳性B细胞,但其在接受稳定肾素-血管紧张素系统抑制剂(RASI)治疗的成人IgAN患者中的疗效尚不明确。本研究旨在评估RTX联合RASI治疗与单用RASI治疗的疗效和安全性。这是一项多中心随机对照试验。研究对象为来自中国10个中心的活检确诊IgAN成人患者,尽管接受≥3个月RASI治疗,其24小时尿总蛋白(UTP)仍>1 g/天,且血压<130/80 mmHg。干预措施为RTX联合RASI与单用RASI,持续12个月。主要结局指标为第12个月时24小时UTP的变化。次要连续变量包括第6个月24小时UTP的变化以及第12个月估算肾小球滤过率(eGFR)和血清Gd-IgA1的变化;次要分类变量包括第6和第12个月24小时UTP减少≥50%的比例、eGFR下降≥50%或血肌酐翻倍,以及终末期肾病(ESKD)。同时记录不良事件、严重不良事件和感染。探索性分析考察了至第24个月的结局。在随机入组的106名参与者(每组53人)中,两组在第12个月时24小时UTP的变化相似(调整后的几何均数比GMR为1.05;95% CI, 0.80-1.36)。RTX组和RASI组的中位24小时UTP变化分别为-0.21 g/天和-0.26 g/天。在eGFR(调整后的均值差为3.80 mL/min/1.73 m2;95% CI, -0.47至8.06)、Gd-IgA1(调整后的GMR为1.04;95% CI, 0.87-1.24)或实现24小时UTP减少≥50%的比例(15.1% vs 20.8%)方面,两组间均未观察到统计学显著差异。两组的不良事件发生率相似;在12个月治疗期间未发生eGFR下降≥50%、血肌酐翻倍或ESKD的事件。这些发现与包含至第24个月结局数据的分析结果一致。随访期相对较短,且仅纳入了亚洲患者。在IgAN患者中,在优化的基于RASI的治疗基础上加用RTX并未观察到蛋白尿的进一步减少或肾功能的保护。本研究获得了政府(国家重点研发计划、中国重大国际[区域]联合研究项目、国家自然科学基金、国家转化医学设施[上海]、上海医苑新星青年人才发展计划)、学术机构(上海申康医院发展中心)和非营利组织(国际肾脏病学会)的资金支持。
In the ISCHEMIA-CKD trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease), at a median follow-up of 2.2 years, the primary composite outcome of death or nonfatal myocardial infarction was similar between an initial invasive strategy (INV) compared with an initial conservative strategy (CON) in patients with moderate or severe myocardial ischemia and advanced chronic kidney disease. However, the long-term outcomes comparing the 2 strategies are unknown. Participants in the ISCHEMIA-CKD trial were randomly assigned to either INV, involving coronary angiography and revascularization when feasible, added to guideline-directed medical therapy or to CON with guideline-directed medical therapy alone and invasive procedures reserved for failure of guideline-directed medical therapy. After the active intervention trial phase, long-term vital status follow-up was conducted through participant contact by participating sites and by health record and centralized death database searches. The primary outcome for the extended follow-up phase was all-cause mortality. Secondary outcomes were cause-specific mortality, including cardiovascular and noncardiovascular mortality. Among the 777 participants randomized (388 to INV and 389 to CON), over a median of 8 years of follow-up, vital status retention among survivors was 95%. There was a total of 429 deaths (55%). Cumulative all-cause mortality (57.4% versus 56.8%; adjusted hazard ratio, 1.05 [95% CI, 0.87-1.28]) or cardiovascular mortality (40.3% versus 38.4%; adjusted hazard ratio, 1.06 [95% CI, 0.84-1.34]) at 8 years did not differ between INV and CON. The restricted mean survival time was 1941 days (1834-2047 days) for INV versus 1990 days (1885-2094 days) for CON, with an adjusted estimated difference of -99 days (-245 to 46). The posterior probability of at least a 1 percentage point lower or higher death with INV at the 8-year median follow-up was 28% and 52%, respectively. Similarly, the posterior probability of at least a 1 percentage point lower or higher cardiovascular mortality with INV was 23% and 56%, respectively. In patients with at least moderate ischemia and advanced chronic kidney disease, there was no significant long-term benefit of an initial INV at reducing the risk of all-cause or cardiovascular mortality compared with an initial conservative strategy. URL: https://www.clinicaltrials.gov; Unique identifier: NCT01985360.
中文摘要:在ISCHEMIA-CKD试验中,对于伴有中度或重度心肌缺血及晚期慢性肾脏病的患者,在中位随访2.2年时,初始侵入性策略与初始保守策略在死亡或非致死性心肌梗死的主要复合终点上相似。然而,这两种策略的长期预后尚不清楚。ISCHEMIA-CKD试验的参与者被随机分配至侵入性组或保守组。侵入性组接受冠状动脉造影及可行的血运重建并联合指南指导的药物治疗;保守组仅接受指南指导的药物治疗,仅在药物疗法失败时考虑侵入性操作。在主动干预阶段结束后,通过参与中心联系患者以及查阅健康记录和中央死亡数据库进行长期生存状态随访。扩展随访阶段的主要终点是全因死亡率。次要终点包括心血管及非心血管特异性死亡率。在777名随机分配的参与者中(388例为侵入组,389例为保守组),在中位随访8年期间,幸存者的生存状态保留率为95%。共有429例死亡(55%)。8年时,侵入组与保守组的全因死亡率(57.4%对56.8%;调整后的风险比1.05 [95% CI, 0.87-1.28])和心血管死亡率(40.3%对38.4%;调整后的风险比1.06 [95% CI, 0.84-1.34])无显著差异。侵入组的限制性平均生存时间为1941天(1834-2047天),保守组为1990天(1885-2094天),调整后的估计差异为-99天(-245至46)。在中位随访8年时,侵入组导致至少1个百分点更低或更高死亡率的概率分别为28%和52%。同样,侵入组导致至少1个百分点更低或更高心血管死亡率的概率分别为23%和56%。对于伴有至少中度缺血及晚期慢性肾脏病的患者,与初始保守策略相比,初始侵入性策略在降低全因或心血管死亡率方面无显著的长期益处。
基础研究 (4篇)
The prevalence of chronic kidney disease (CKD) in aging felids is three- to four-fold higher than in other mammals, including humans. Regardless of species, serum and urinary biomarkers of CKD become effective only when little can be done to reverse progression. We propose that felids, as super water conservers and obligate hyper-carnivores, are naturally prone to form cytoplasmic lipid droplets (LDs) in their kidney cells, which predisposes felids to age-associated CKD. Furthermore, we offer a novel mechanistic basis for renal LD formation in felids. Presence of LDs in felid urine-lipuria, which is uncommon in all other mammals-could be the earliest biomarker of metabolic events in kidney cells that underpin CKD. Felids have unique anatomical, physiological, nutritional, and metabolic features, including synthesis and subsequent excretion of felinine together with branched-chain fatty acids into urine. These features offer a unique opportunity for early intervention but also are of interest in the context of comparative biology, nephrology, and renal disease.
中文摘要:衰老猫科动物中慢性肾脏病(CKD)的患病率是包括人类在内的其他哺乳动物的三到四倍。无论物种如何,血清和尿液中的 CKD 生物标志物仅在逆转进展的可能性极小时才有效。我们提出,作为超级保水动物和专性高肉食动物,猫科动物天生容易在其肾细胞中形成胞质脂滴(LDs),这使猫科动物易患与年龄相关的 CKD。此外,我们提供了猫科动物肾脏 LD 形成的新机制基础。猫科动物尿液中存在 LDs(尿脂症),这在所有其他哺乳动物中并不常见,这可能是支持 CKD 的肾细胞代谢事件的最早生物标志物。猫科动物具有独特的解剖、生理、营养和代谢特征,包括合成芬宁并将其与支链脂肪酸一起排泄到尿液中。这些特征为早期干预提供了独特机会,并在比较生物学、肾脏病学和肾脏疾病的背景下引起关注。
Kidney outcome trials demonstrate that sodium-glucose cotransporter 2 inhibitors consistently slow chronic kidney disease progression; however, the underlying mechanisms remain incompletely defined, as benefits extend beyond glycemic control and hemodynamic effects across diabetic and non-diabetic chronic kidney disease. This review advances a unifying framework in which metabolic unloading of the proximal tubule contributes to renoprotection. The metabolic burden of solute reabsorption places the proximal tubule at the center of renal energetics, predisposing it to hypoxia, mitochondrial stress, and maladaptive injury responses. We synthesize evidence that these agents reduce adenosine triphosphate-dependent transport workload, oxygen consumption and may also reduce megalin-dependent endocytosis, with downstream effects on mitochondrial efficiency, redox balance, and autophagy/mitophagy supported by emerging preclinical data. By mitigating energetic stress, these agents divert tubular cell fate away from maladaptive hypertrophy and fibrosis toward adaptive repair. This framework integrates spatial cortex-medulla vulnerability, reconciles early hemodynamic changes with durable slowing of estimated glomerular filtration rate decline, and explores disease-agnostic benefit. We discuss translational implications including early initiation, identification of high workload phenotypes (hyperfiltration, recovery after acute kidney injury), and deployment of energetics associated biomarkers such as ketones, oxidative stress profiles, and estimated glomerular filtration rate slope. This review positions cellular energetics as an important upstream constraint shaping kidney disease progression, offering a foundation for nephroprotective strategies.
中文摘要:肾脏结局试验表明,钠葡萄糖协同转运蛋白2抑制剂能持续减缓慢性肾脏病的进展。然而,其潜在机制仍未完全明确,因为其在糖尿病和非糖尿病性慢性肾脏病中的益处超出了血糖控制和血流动力学效应的范畴。本综述提出了一个统一框架,认为近端小管的代谢卸载有助于肾脏保护。溶质重吸收的代谢负担使近端小管处于肾脏能量代谢的核心位置,使其易受缺氧、线粒体应激和适应性不良损伤反应的影响。我们综合了现有证据,表明这些药物降低了依赖三磷酸腺苷的运输负荷和氧气消耗,并可能减少依赖于megalin的内吞作用。下游对线粒体效率、氧化还原平衡以及自噬/线粒体自噬的影响得到了新兴临床前数据的支持。通过减轻能量应激,这些药物将肾小管细胞的命运从适应性不良的肥大和纤维化转向适应性修复。该框架整合了皮髓质易感性的空间差异,调和了早期血流动力学变化与估算肾小球滤过率下降持续减缓之间的关系,并探讨了疾病非特异性的益处。我们讨论了转化意义,包括早期启动治疗、识别高负荷表型(如高滤过、急性肾损伤后恢复)以及部署能量相关生物标志物(如酮体、氧化应激谱和估算肾小球滤过率斜率)。本综述将细胞能量代谢定位为塑造肾脏疾病进展的重要上游约束因素,为肾脏保护策略提供了基础。
Endotrophin (ETP), a C-terminal cleavage fragment of the collagen VI α3 chain, has emerged as a key mediator of fibroinflammation and a clinically relevant biomarker of disease progression. Accumulating evidence from both preclinical models and human studies implicates elevated ETP levels as a driver of tissue remodelling, metabolic dysfunction, inflammation and fibrosis across multiple organ systems. Increased ETP has been linked to obesity-associated adipose tissue dysfunction, steatotic liver disease, breast cancer progression, chronic kidney disease and cardiovascular disease, underscoring its broad pathological relevance. The convergence of mechanistic and clinical data positions ETP as a promising therapeutic target across a range of diseases linked by common ETP-driven dysfunction. Here we synthesize current knowledge of ETP's regulation and functions, critically evaluate its role in diverse disease contexts and outline key unanswered questions and emerging strategies for therapeutic intervention.
中文摘要:内皮素(ETP)是胶原VIα3链的C端裂解片段,已成为纤维炎症的关键介质及疾病进展的临床相关生物标志物。来自临床前模型和人类研究的累积证据表明,升高的ETP水平是驱动多器官系统中组织重塑、代谢功能障碍、炎症和纤维化的因素。ETP增加与肥胖相关的脂肪组织功能障碍、脂肪性肝病、乳腺癌进展、慢性肾脏病和心血管疾病有关,突显了其广泛的病理相关性。机制数据和临床数据的汇聚使ETP成为针对由共同ETP驱动功能障碍联系的一系列疾病的有前景的治疗靶点。本文综合了关于ETP调节和功能的知识,批判性地评估了其在不同疾病背景下的作用,并概述了关键未解问题和治疗干预的新兴策略。
Vascular calcification is a hallmark of chronic kidney disease (CKD)-mineral and bone disorder and a major determinant of cardiovascular mortality. Secondary calciprotein particles (CPP2) are key mediators of vascular calcification; however, the mechanisms regulating their maturation and pathogenic properties remain incompletely understood. CPT (Calprotectin, S100A8/A9), a myeloid-derived inflammatory mediator, is elevated in CKD and predicts cardiovascular events and mortality, particularly under high-phosphate conditions, but the underlying mechanisms remain unclear. We investigated the role of CPT in vascular calcification using CKD-mineral and bone disorder mice with myeloid-specific CPT deletion. Aortic calcification was assessed by ex vivo imaging, histology, and calcium quantification. Serum calciprotein particle (CPP) fractions were determined by flow cytometry. Mechanistic studies were performed in vascular smooth muscle cells exposed to CPP2 in the presence or absence of macrophage-derived CPT. Calcification propensity was evaluated using the T50 assay, and CPP2 elemental composition was analyzed by high-angle annular dark-field scanning transmission electron microscopy-energy-dispersive X-ray spectroscopy. Myeloid-specific CPT deletion significantly attenuated aortic calcification and osteogenic gene expression in CKD-mineral and bone disorder mice without altering renal function or systemic mineral parameters. These changes were accompanied by an increased circulating immature CPP fraction. Macrophage-derived CPT markedly enhanced CPP2-induced vascular smooth muscle cell calcification by accelerating CPP maturation, reflected by a shortened T50, and by altering CPP2 composition to be enriched in calcium and phosphate. Although no direct interaction between CPT and CPPs was detected, CPT modified the physicochemical milieu, including ionized calcium and pH. Consistently, CPP2 from CPT-deficient serum exhibited substantially reduced calcification potency, indicating that CPT shapes CPP pathogenicity by modulating particle quality rather than quantity. Importantly, CPT-mediated CPP maturation occurred in a cell-free milieu, indicating a TLR4-independent mechanism distinct from its known receptor-mediated actions. CPT is a previously unrecognized regulator of pathogenic CPP maturation and composition, thereby promoting vascular calcification in CKD-mineral and bone disorder. Targeting CPT may represent a novel therapeutic strategy to attenuate vascular calcification in CKD.
中文摘要:血管钙化是慢性肾脏病(CKD)矿物质和骨紊乱的标志,也是心血管死亡率的主要决定因素。继发性钙蛋白颗粒(CPP2)是血管钙化的关键介质,但其成熟机制及致病特性尚不完全清楚。CPT(Calprotectin,S100A8/A9)是一种髓系来源的炎症介质,在CKD患者中升高并预测心血管事件和死亡率,特别是在高磷条件下,但其潜在机制仍不清楚。本研究利用髓系特异性CPT缺失的CKD矿物质和骨紊乱小鼠模型,探究了CPT在血管钙化中的作用。通过体外成像、组织学和钙定量评估主动脉钙化。采用流式细胞术测定血清钙蛋白颗粒(CPP)组分。在有无巨噬细胞来源CPT存在的情况下,对暴露于CPP2的血管平滑肌细胞进行机制研究。使用T50试验评估钙化倾向,并通过高角环形暗场扫描透射电子显微镜-能量色散X射线光谱分析CPP2的元素组成。髓系特异性CPT缺失显著减轻了CKD矿物质和骨紊乱小鼠的主动脉钙化和成骨基因表达,且未改变肾功能或全身矿物质参数。这些变化伴随循环中未成熟CPP比例的增加。巨噬细胞来源的CPT通过加速CPP成熟(表现为T50缩短)并改变CPP2成分使其富含钙和磷酸盐,显著增强了CPP2诱导的血管平滑肌细胞钙化。尽管未检测到CPT与CPPs之间的直接相互作用,但CPT改变了理化环境,包括离子钙和pH值。一致地,来自CPT缺陷血清的CPP2表现出显著降低的钙化潜能,表明CPT通过调节颗粒质量而非数量来塑造CPP的致病性。重要的是,CPT介导的CPP成熟发生在无细胞环境中,表明这是一种不同于其已知受体介导作用的TLR4非依赖性机制。CPT是CPP成熟和组成的先前未被认识的调节因子,从而促进CKD矿物质和骨紊乱中的血管钙化。靶向CPT可能代表一种减轻CKD血管钙化的新型治疗策略。
2基础/转化研究 (3篇)
基础研究 (3篇)
The molecular pathways in endothelial cells (ECs) in diabetic nephropathy (DN), a primary microvascular complication of diabetes, remain unclear. Tissue KLKs (kallikrein-related peptidases) participate in pathophysiological processes in ECs. We aimed to explore the roles of endothelial KLKs in DN and define the underlying mechanisms. Renal KLK8 was the most highly upregulated KLK in streptozotocin-induced diabetic mice and cultured glomerular ECs (GECs) upon high glucose treatment. C57/BL6 background global (Klk8-/-) and endothelial Klk8 knockout (Klk8ΔEC) mice, as well as DBA/2J mice with endothelial Klk8 knockdown, displayed improved albuminuria, mesangial matrix expansion, and glomerulosclerosis caused by streptozotocin compared with the corresponding wild-type mice. Single-cell RNA sequencing showed that many pathways linked to DN in ECs, mesangial cells, and tubule cells were reversed in Klk8ΔEC mice. Endothelial-to-mesenchymal transition caused by streptozotocin was extensively improved in Klk8ΔEC mice, which was confirmed in Cdh5CreERT2+/--mT/mG+/- mice with endothelial Klk8 knockdown. Proteome coupled with other approaches revealed that KLK8 cleaved SDC4 (syndecan-4), which contributed to the loss of glycocalyx integrity in GECs during DN progress. Lifr was one of the key genes in ECs and mesangial cells regulated by endothelial Klk8 during DN progress. Endothelial KLK8 upregulated LIFR (leukemia inhibitory factor receptor) expression through PLC (phospholipase C)/ERK (extracellular signal-regulated kinase)/RUNX1 (runt-related transcription factor)1 pathways, and upregulated LIFR contributed to high glucose-induced GEC dysfunction and MC activation. Knockdown of Lifr ameliorated hallmark features of DN and improved endothelial-to-mesenchymal transition and SDC4 expression in the glomeruli of diabetic mice. LIFR was upregulated in GECs and mesangial cells in patients with DN. Circulatory LIF (leukemia inhibitory factor), KLK8 and soluble SDC4 levels were increased in patients with DN, and KLK8 level was positively correlated with LIF, soluble SDC4 and creatinine levels. Endothelial KLK8 promotes GEC dysfunction and abnormal crosstalk with mesangial cells through a LIFR-dependent signaling in DN, which immediately highlights therapeutic targets for DN.
中文摘要:糖尿病肾病是糖尿病主要的微血管并发症,其内皮细胞中的分子通路尚不明确。组织激肽释放酶相关肽酶参与内皮细胞的病理生理过程。本研究旨在探讨内皮激肽释放酶在糖尿病肾病中的作用并阐明潜在机制。链脲佐菌素诱导的糖尿病小鼠及高糖处理的培养肾小球内皮细胞中,肾脏KLK8上调最为显著。与野生型小鼠相比,C57/BL6背景下的全身Klk8敲除小鼠、内皮特异性Klk8敲除小鼠以及内皮Klk8敲低的DBA/2J小鼠表现出改善的白蛋白尿、系膜基质扩张和肾小球硬化。单细胞RNA测序显示,Klk8ΔEC小鼠中许多与糖尿病肾病相关的内皮细胞、系膜细胞和肾小管细胞通路发生逆转。链脲佐菌素引起的内皮间质转化在Klk8ΔEC小鼠中得到显著改善,该结果在内皮Klk8敲低的Cdh5CreERT2+/--mT/mG+/-小鼠中得到证实。蛋白质组学结合其他方法显示,KLK8切割SDC4(syndecan-4),导致糖尿病肾病进展过程中肾小球内皮细胞糖萼完整性丧失。Lifr是糖尿病肾病进展过程中受内皮KLK8调控的内皮细胞和系膜细胞的关键基因之一。内皮KLK8通过PLC/ERK/RUNX1通路上调LIFR表达,而LIFR的上调有助于高糖诱导的肾小球内皮细胞功能障碍和系膜细胞激活。敲低Lifr改善了糖尿病小鼠肾脏标志性的糖尿病肾病特征,并改善了内皮间质转化及SDC4在肾小球中的表达。糖尿病肾病患者的肾小球内皮细胞和系膜细胞中LIFR表达上调。糖尿病肾病患者的循环LIF、KLK8和可溶性SDC4水平升高,且KLK8水平与LIF、可溶性SDC4和肌酐水平呈正相关。内皮KLK8通过LIFR依赖性信号通路促进肾小球内皮细胞功能障碍及与系膜细胞的异常串扰,这为糖尿病肾病的治疗靶点提供了重要启示。
Golden Flower Tibetan Tea polysaccharide components (GFTTPs) are polysaccharide-rich matrices generated during standardised "flowering" fermentation and may co-exist with tea pigments, phenolics and proteins. This study aimed to characterise GFTTPs and evaluate their metabolic effects in high-fat diet (HFD)-induced obese mice. GFTTPs were prepared by hot-water extraction, ethanol precipitation and dialysis, followed by compositional analysis and structural fingerprinting using FTIR, XRD, SEM, TGA/DTG and Py-GC/MS. GFTTPs exhibited an acidic, GalUA-rich composition with a medium-to-low molecular-weight distribution, predominantly amorphous organisation and an apparent porous morphology after freeze-drying. In vitro, GFTTPs showed concentration-dependent DPPH and ABTS radical-scavenging activities and FRAP reducing power, while α-glucosidase inhibition was modest compared with acarbose. In HFD-induced obese mice, 6-week administration of GFTTPs (600 mg kg-1 day-1) improved glucose tolerance and insulin responsiveness, reduced OGTT and IPITT AUCs, and improved fasting insulin-derived indices. GFTTPs also alleviated dyslipidaemia and transaminase elevation, accompanied by improved liver and pancreatic histopathology. Inflammatory and redox responses were partly restored, as shown by reduced TNF-α, increased IL-4, and recovered serum CAT and SOD activities, whereas IL-6 and MDA were less responsive. Microbiota and SCFA analyses indicated partial reversal of HFD-associated dysbiosis and SCFA remodelling, particularly increases in valerate and butyrate. Integrated correlation patterns suggested association-based links among gut microbiota, SCFAs and host metabolic phenotypes. Overall, GFTTPs provide a composition- and structure-characterised polysaccharide-rich tea-derived matrix with potential functional-food applications for metabolic health management.
中文摘要:金花藏茶多糖组分(GFTTPs)是在标准化「开花」发酵过程中产生的富含多糖的基质,可能与茶色素、酚类物质和蛋白质共存。本研究旨在表征GFTTPs并评估其在高脂饮食(HFD)诱导的肥胖小鼠中的代谢效应。通过热水提取、乙醇沉淀和透析制备GFTTPs,并利用傅里叶变换红外光谱(FTIR)、X射线衍射(XRD)、扫描电子显微镜(SEM)、热重/差热分析(TGA/DTG)及裂解气相色谱-质谱(Py-GC/MS)进行成分分析和结构指纹图谱绘制。结果显示,GFTTPs呈酸性,富含半乳糖醛酸(GalUA),分子量分布中等偏低,主要为无定形结构,冻干后呈现明显的多孔形态。体外实验表明,GFTTPs表现出浓度依赖性的DPPH和ABTS自由基清除活性及FRAP还原力,而α-葡萄糖苷酶抑制作用与阿卡波糖相比相对温和。在HFD诱导的肥胖小鼠中,连续6周给予GFTTPs(600 mg kg-1 day-1)改善了葡萄糖耐量和胰岛素反应性,降低了口服葡萄糖耐量试验(OGTT)和胰岛素耐量试验(IPITT)的面积曲线下值(AUC),并改善了空腹胰岛素衍生指标。GFTTPs还缓解了血脂异常和转氨酶升高,伴随肝脏和胰腺组织病理学的改善。炎症和氧化还原反应部分恢复,表现为TNF-α降低、IL-4增加以及血清CAT和SOD活性恢复,而IL-6和MDA的反应性较低。微生物群和短链脂肪酸(SCFA)分析表明,HFD相关的菌群失调和部分SCFA重塑得到逆转,特别是戊酸和丁酸的增加。综合相关性模式提示肠道微生物群、SCFA与宿主代谢表型之间存在基于关联的联系。总体而言,GFTTPs提供了一种成分和结构特征明确的富含多糖的茶源基质,具有在代谢健康管理中作为功能性食品应用的潜力。
Conventional alkaline extraction-isoelectric precipitation can induce protein denaturation and reassociation via pronounced pH shifts. Herein, betaine/urea deep eutectic solvent (DES-2)-assisted extraction was combined with membrane filtration and direct dialysis for non-precipitative soy protein recovery. The recovered protein showed purity comparable with that obtained via conventional alkaline extraction-isoelectric precipitation (85.09% ± 0.68% vs 85.91% ± 0.74%) and a higher yield (17.45% ± 0.95% vs 13.65% ± 1.35%). Quantum chemical calculations showed that betaine and urea formed a stable hydrogen-bonded network. Molecular dynamics simulations of 11S glycinin indicated enhanced solvation and conformational relaxation with increased radius of gyration and solvent-accessible surface area. Directly dialysed DES-extracted protein showed smaller particle size; less subunit reassociation; lower disulphide bond content; higher free sulphydryl group content; and improved solubility, foaming and emulsifying properties than commercial soy protein isolate. DES-2-assisted extraction combined with direct dialysis may improve soy protein recovery and techno-functional properties.
中文摘要:传统的碱提等电沉淀法可能因显著的pH变化导致蛋白质变性和再聚集。本研究结合膜过滤和直接透析,采用甜菜碱/尿素深共晶溶剂(DES-2)辅助提取以实现大豆蛋白的非沉淀回收。回收蛋白的纯度与传统碱提等电沉淀法相当(85.09%±0.68% vs 85.91%±0.74%),且得率更高(17.45%±0.95% vs 13.65%±1.35%)。量子化学计算表明甜菜碱和尿素形成了稳定的氢键网络。11S大豆球蛋白的分子动力学模拟显示,其溶剂化程度增强,构象松弛,回转半径和溶剂可及表面积增大。经直接透析的DES提取蛋白与商业大豆分离蛋白相比,粒径更小;亚基再聚集更少;二硫键含量更低;游离巯基含量更高;溶解性、发泡性和乳化性得到改善。DES-2辅助提取结合直接透析可能提高大豆蛋白的回收率和技术功能特性。
3急性肾损伤 AKI (2篇)
临床研究 (2篇)
A meta-analysis in a recent issue of the British Journal of Anaesthesia pools randomised evidence on intraoperative arterial blood pressure targets in nine trials in noncardiac surgery. With a total of 14 658 patients included in the analysis, the authors show that higher mean arterial pressure targets do not reduce 30-day mortality, acute kidney injury, or myocardial injury. These findings reinforce the distinction between low blood pressure as a marker of perioperative vulnerability and low blood pressure as a modifiable therapeutic target. Correcting arterial pressure might normalise a number without removing the underlying physiological vulnerability that drives adverse postoperative outcomes. Therefore, this meta-analysis supports a shift from reflexive increases in blood pressure targets towards attention to the underlying cause of haemodynamic instability.
中文摘要:近期《英国麻醉学杂志》发表的一项荟萃分析汇总了九项非心脏手术中术中动脉血压目标的随机试验证据。该分析共纳入14658名患者,结果显示较高的平均动脉压目标并不能降低30天死亡率、急性肾损伤或心肌损伤的发生率。这些发现强化了低血压作为围术期脆弱性标志与低血压作为可改变的治疗目标之间的区别。纠正动脉压可能仅使数值恢复正常,而未去除驱动不良术后结局的潜在生理脆弱性。因此,该荟萃分析支持将血压目标从反射性提高转向关注血流动力学不稳定的根本原因。
The best management approach for renin-angiotensin system (RAS) inhibitor use before surgery is controversial. Some studies have suggested that continuation could increase the risk of clinically significant peri-operative hypotension and, thus, organ injury. By contrast, others believe that withholding them significantly increases the risk of severe hypertension and heart failure. To determine the most effective strategy, this systematic review and meta-analysis of randomized controlled trials compared discontinuation vs continuation of RAS inhibitors in patients undergoing non-cardiac and non-vascular surgeries. PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) databases were searched for randomized controlled trials that compared discontinuation vs continuation of RAS inhibitors in patients undergoing non-cardiac and non-vascular surgery. Five randomized controlled trials (n = 10 773 patients; 5388 randomized to discontinuation) were included. Discontinuation of an RAS inhibitor probaby reduced peri-operative hypotension (27.66% vs 34.06%; risk ratio [RR] 0.81, 95% confidence interval [CI] 0.73-0.89; moderate certainty). The evidence is very uncertain about effects on peri-operative hypertension (9.46% vs 8.05%; RR 1.38, 95% CI 0.66-2.89; very low certainty). For major clinical outcomes, discontinuation suggested little to no difference in acute kidney injury (10.45% vs 10.69%; RR 0.98, 95% CI 0.66-1.45; low certainty), acute heart failure (5.38% vs 5.32%; RR 1.00, 95% CI 0.76-1.31; low certainty), myocardial infarction (1.22% vs 1.00%; RR 1.19, 95% CI 0.60-2.39; low certainty), stroke (0.42% vs 0.40%; RR 1.04, 95% CI 0.56-1.93; low certainty), and arrhythmias (1.80% vs 1.40%; RR 1.28, 95% CI 0.69-2.38; low certainty). These findings suggest that discontinuation of RAS inhibitors is likely to reduce peri-operative hypotension in patients undergoing non-cardiac, non-vascular surgery, but the evidence is very uncertain about effects on peri-operative hypertension and major clinical outcomes.
中文摘要:手术前肾素-血管紧张素系统(RAS)抑制剂的最佳管理方法存在争议。一些研究表明,继续用药可能增加临床显著性围术期低血压及器官损伤的风险;另一些则认为停药会显著增加严重高血压和心力衰竭的风险。为确定最有效的策略,本研究对随机对照试验进行了系统综述和荟萃分析,比较了接受非心脏和非血管手术患者中停用与继续使用RAS抑制剂的差异。检索PubMed、Embase和Cochrane对照试验中心注册库(CENTRAL)中关于非心脏和非血管手术患者停用与继续用药的随机对照试验。纳入五项随机对照试验(共10773名患者,其中5388名被随机分配至停药组)。停用RAS抑制剂可能降低围术期低血压发生率(27.66% vs 34.06%;风险比[RR] 0.81,95%置信区间[CI] 0.73-0.89;中等确定性证据)。关于对围术期高血压的影响,证据非常不确定(9.46% vs 8.05%;RR 1.38,95% CI 0.66-2.89;极低确定性证据)。在主要临床结局方面,停药显示急性肾损伤(10.45% vs 10.69%;RR 0.98,95% CI 0.66-1.45;低确定性)、急性心力衰竭(5.38% vs 5.32%;RR 1.00,95% CI 0.76-1.31;低确定性)、心肌梗死(1.22% vs 1.00%;RR 1.19,95% CI 0.60-2.39;低确定性)、卒中(0.42% vs 0.40%;RR 1.04,95% CI 0.56-1.93;低确定性)和心律失常(1.80% vs 1.40%;RR 1.28,95% CI 0.69-2.38;低确定性)差异很小或无差异。这些发现表明,对于接受非心脏、非血管手术的患者,停用RAS抑制剂可能降低围术期低血压风险,但关于其对围术期高血压及主要临床结局影响的证据非常不确定。
4肾移植 (1篇)
基础研究 (1篇)
Inflammasomes are classically understood as canonical complexes assembled around individual cytosolic sensors, such as NLRP3, NLRP1, NLRC4, AIM2, or Pyrin. This view has been highly productive, but accumulating evidence suggests that it may be incomplete. Several reports now support physical or functional cooperation between distinct innate immune receptors, including NLRC4-NLRP3 co-recruitment, NLRP3-dependent licensing by NLRP11, inhibitory interaction between NLRP12 and NLRP3, and cooperation between NOD2 and NLRP1. More recently, biochemical, structural and functional evidence has supported the existence of a hybrid NLRP1-NLRP3 inflammasome in human macrophages and monocytes, with additional support from clinical samples from patients with inflammasomopathies and kidney transplantation. Here, we argue that these findings fit within a broader conceptual framework in which inflammasome sensors form higher-order supramolecular assemblies, or superinflammasomes, conceptually analogous to mitochondrial respiratory supercomplexes. We propose that this organizational layer may enable signal integration, amplification, kinetic tuning, structural plasticity, and inflammatory persistence in disease. This perspective calls for revising the one-sensor-one-inflammasome paradigm and suggests new opportunities for therapeutic intervention.
中文摘要:炎症小体传统上被理解为由单个胞质传感器如NLRP3、NLRP1、NLRC4、AIM2或Pyrin组装而成的经典复合物。这一观点极具生产力,但越来越多的证据表明其可能不完整。多项报告支持不同先天免疫受体之间存在物理或功能合作,包括NLRC4与NLRP3的共同招募、NLRP1对NLRP3的依赖性许可、NLRP12与NLRP3之间的抑制性相互作用以及NOD2与NLRP1的合作。最近生化、结构和功能证据支持在人巨噬细胞和单核细胞中存在混合型NLRP1-NLRP3炎症小体,来自炎症小体病和肾移植患者的临床样本也提供了额外支持。我们认为这些发现符合更广泛的概念框架,其中炎症小体传感器形成高阶超分子组装体或称为超级炎症小体,概念上类似于线粒体呼吸超复合物。我们提出这种组织层级可能实现信号整合、放大、动力学调节、结构可塑性及疾病中的炎症持续性。这一视角呼吁修正单传感器单炎症小体的范式并提示治疗干预的新机会。
5肾小球疾病 (1篇)
基础研究 (1篇)
IgA nephropathy is the most common primary glomerular nephritis worldwide and remains one of the leading causes of kidney failure. Although IgA nephropathy is a heterogeneous disease, glomerular deposition of galactose-deficient IgA1 (Gd-IgA1) is considered a pathological feature shared across the disease. This pathological hallmark underpins the multihit hypothesis of IgA nephropathy and has driven the development of therapies targeting Gd-IgA1 production, several of which have recently demonstrated clinical efficacy and received regulatory approval. These advances provide a timely opportunity to re-evaluate the role of Gd-IgA1 in the pathogenesis of IgA nephropathy. Notably, analysis of longitudinal changes in serum Gd-IgA1 levels and proteinuria reported in recent therapeutic trials raises the possibility that only a subset of circulating Gd-IgA1, rather than the entire circulating Gd-IgA1 pool, may drive glomerular inflammation leading to hematuria and/or proteinuria in IgA nephropathy. In this review, we propose the concept of "pathogenic Gd-IgA1" to describe this disease-relevant subset and highlight three potential features: a mucosal origin, molecular properties that promote selective mesangial deposition, and the capacity to form immune complexes and activate the complement system. This conceptual framework may deepen our understanding of IgA nephropathy pathogenesis, help optimize the use of emerging therapies, and facilitate the development of novel therapies that selectively target pathogenic Gd-IgA1.
中文摘要:IgA肾病是全球最常见的原发性肾小球肾炎,仍是导致肾衰竭的主要原因之一。尽管IgA肾病是一种异质性疾病,但半乳糖缺陷型IgA1(Gd-IgA1)在肾小球的沉积被视为该疾病共有的病理特征。这一病理标志构成了IgA肾病多击假说的基础,并推动了针对Gd-IgA1产生的疗法开发,其中几种疗法近期已显示出临床疗效并获得监管批准。这些进展为重新评估Gd-IgA1在IgA肾病发病机制中的作用提供了及时的机会。值得注意的是,对近期治疗试验中报告的血清Gd-IgA1水平纵向变化与蛋白尿的分析表明,可能只有循环Gd-IgA1的一个亚群而非全部循环Gd-IgA1库驱动了导致IgA肾病血尿和/或蛋白尿的肾小球炎症。在本综述中,我们提出「致病性Gd-IgA1」的概念来描述这一与疾病相关的亚群,并强调其三个潜在特征:黏膜来源、促进选择性系膜沉积的分子特性以及形成免疫复合物并激活补体系统的能力。这一概念框架可能加深我们对IgA肾病发病机制的理解,帮助优化新兴疗法的使用,并促进选择性靶向致病性Gd-IgA1的新型疗法的开发。
6透析 (1篇)
基础研究 (1篇)
Reliable vascular access is vital for patients undergoing hemodialysis. Current arteriovenous shunts (AVS) made of expanded polytetrafluoroethylene (ePTFE) are prone to thrombosis, intimal hyperplasia, and infections. To overcome these limitations, biological Tissue-Engineered Vascular Grafts (TEVGs) were produced by weaving threads made from Cell-Assembled extracellular Matrix (CAM), i.e., extracellular matrix produced by ovine fibroblasts in culture. The woven TEVGs were designed with a 6 mm internal diameter and beveled ends to facilitate use as an AVS. They had a burst pressure (3069 ± 546 mmHg) and a compliance (4.4 ± 0.5%/100 mmHg) closer to those of native blood vessels than ePTFE prostheses. Woven TEVGs were implanted as carotid-jugular AVS in sheep and compared to ePTFE controls in a bilateral model (n = 8 animals). Grafts were easily punctured with 16G hemodialysis needles once at 4 weeks without loss of structural integrity or hemorrhagic complications. Overall TEVGs patency was 100%, while it was 87.5% for ePTFE grafts (n = 8). Histological analysis revealed an inflammatory response that decreased between 4 and 8 weeks. A luminal neotissue was observed at 8 weeks with smooth muscle cells and localized endothelialization. Localized calcification of CAM was observed and appeared to be correlated with high tissue compaction. This proof-of-concept study demonstrates the feasibility of using a completely biological TEVG made from woven CAM as an AVS in an allogeneic large animal model. Future studies are needed to understand and avoid the never-before-observed calcification of the CAM in a large animal model, as well as to determine longer-term outcomes.
中文摘要:可靠的血管通路对于接受血液透析的患者至关重要。目前由膨体聚四氟乙烯(ePTFE)制成的动静脉分流器易发生血栓形成、内膜增生和感染。为克服这些局限性,本研究通过编织由细胞组装细胞外基质(CAM)制成的线(即在培养中由绵羊成纤维细胞产生的细胞外基质)来制造生物组织工程血管移植物(TEVG)。编织的TEVG设计为6毫米内径和斜切端,以便于用作动静脉分流器。其爆破压(3069±546 mmHg)和顺应性(4.4±0.5%/100 mmHg)比ePTFE假体更接近天然血管。将编织的TEVG作为颈静脉-颈动脉动静脉分流器植入绵羊体内,并在双侧模型中与ePTFE对照组进行比较(n=8只动物)。在4周时,移植物可被16G血液透析针轻松穿刺,且无结构完整性丧失或出血并发症。TEVG的整体通畅率为100%,而ePTFE移植物的通畅率为87.5%(n=8)。组织学分析显示炎症反应在4至8周之间减少。在8周时观察到管腔新生组织,包含平滑肌细胞和局部内皮化。观察到CAM的局部钙化,似乎与高组织致密性相关。这项概念验证研究证明了在异种大型动物模型中使用完全由编织CAM制成的生物TEVG作为动静脉分流器的可行性。未来研究需要了解和避免在大型动物模型中从未观察到的CAM钙化现象,并确定长期结果。